New Diagnostic Test for Cancer Metastasis

17 Jun 2014
Kerry Parker
CEO

Product news

A new study has proven that a new diagnostic cancer test is more accurate in predicting the risk of breast cancer metastatic tumor spread than a test closely resembling the leading breast cancer prognostic indicator on the market.

Astudy led by Thomas Rohan, MD, PhD, Professor and Chair of Epidemiology and Population Health at the Albert Einstein Cancer Center of Yeshiva University and Montefiore Einstein Center for Cancer Care, has identified a new test for metastatic risk in the Journal of the National Cancer Institute (JNCI).

The new diagnostic cancer test was trialed on approximately 500 breast tumor specimens that had been collected over a 20-year period. The test was proven to be more accurate in predicting the risk of metastatic tumor spread than a test closely resembling the leading breast cancer prognostic indicator on the market. Dr Rohan indicated that such tests of metastatic risk can help doctors to identify which patients should receive aggressive therapy and which patients should be spared the treatment.

Clinical Imaging Technology
One of the authors of the study, Joan Jones, MD, senior author of the JNCI paper, Professor of Pathology of Anatomy and Structural Biology, and of Epidemiology and Population Health at Einstein, and Attending Pathologist at Montefiore Medical Center, describes the difference between their test and those currently available on the market. Current tests “assess risk for breast cancer metastasis by looking for changes in gene expression, or in levels of proteins associated with growth of tumor cells." She talks about the mechanism for tumor invasion of blood vessels and how these tests do not reflect this mechanism, adding: “By contrast, our test is based on what Einstein researchers learned from intravital imaging, which reveals biological processes deep within the tissues of a living animal. Using this technology, they determined how breast cancer tumor cells spread in rodents."

This novel technology has shown that primary breast cancers metastasize when a specific trio of cells is present together in the space called a tumor microenvironment of metastasis, or TMEM. This trio of cells and the presence of the protein Mena allows the tumor cell to spread into the bloodstream. The trio of cells has been observed in living rodents using a triple antibody-based immunostain with clinical imaging technology in Einstein's Integrated Imaging Program (IIP).

Breast Cancer Patient Study
The JNCI paper describes results from a blind case-control study that evaluated tumor samples from a subset of women with diagnosed invasive ductal carcinoma of the breast. TMEM testing was carried out on specimens from women who later developed a distant metastasis (the cases) and on specimens from women who were alive and had not developed a distant metastasis (the controls). Controls were individually matched with cases so that women in each pair were the same age and were diagnosed with breast cancer in the same year. The pathology team applied the triple immunostain to specimens and counted the TMEMs using clinical imaging technology.

The TMEM test performed well at assessing metastatic risk for the study's most populous cancer subgroup: women with estrogen receptor positive/HER2- disease (i.e., their cancer cells possess estrogen receptors but lack HER2 protein). For comparison, all tumor specimens included in the study were also analyzed by the previously validated IHC4 test, which measures levels of protein in breast-tumor tissue.

Findings and Outcome
The study findings showed there was little agreement between the TMEM test and the IHC4 test regarding prediction of metastatic risk. TMEM results were highly statistically significant, while IHC4 scores were borderline significant at best.

With further validation and clinical studies, the findings suggest that the TMEM diagnostic assay test could be used to reduce the incidence of overtreatment in early stage breast cancer, and help to guide physicians with treatment decisions in women with breast cancer.

(Article based upon the Eureka article: Study: New test predicts if breast cancer will spread)
Image Credit: Albert Einstein College of Medicine

Links

Tags

Cellular PathologyCellular Pathology deals with the microscopic analysis of tissue samples and cells. Sample preparation and processing includes fixation, staining, sectioning and slide mounting, using equipment such microtomes and cryostats. In choosing immunohistochemistry and immunocytochemistry kits, consider chromogens, staining method, antibodies, microscopes and imaging.Cell-Based AssaysCell-based assays are used to monitor the presence, quantity and activities of a desired cellular analyte including drug molecules or biomarkers. This can reveal information on cell health (apoptosis, cytotoxicity, viability and proliferation assays), cell metabolism, cell migration and cell signaling mechanisms. Find the best cell-based assay products, kits and equipment with our peer reviewed product directory: compare products, check customer reviews and receiving pricing direct from manufacturers.Point-of-CarePoint-of-Care Testing (POCT) or Near Patient Testing (NPT) products are available for urine, blood and other clinical chemistry analyses. POCT includes: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing (PT / INR), rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.In Vivo Imaging Systems<i>In vivo</i> imaging systems, including pre-clinical imaging systems and medical imaging systems are used to non-invasively visualize and capture images of live animals and plants. Monitor the natural processes or diseases of your subjects using small-animal pre-clinical imaging systems, including single photon positron emission tomography (SPECT), positron emission tomography (PET), computed tomography (micro-CT), magnetic resonance imaging (MRI), X-ray radiography, ultrasound, fluorescence and bioluminescence imagers. Multimodal systems and software solutions are also available for correlative analysis of organ, tissue, cell, or molecular-level processes. Find the best in vivo imaging products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Light MicroscopyLight microscopes or optical microscopes are used to visualize microscale objects under magnification, including cells, clinical specimens and materials. Lab equipment for light microscopy includes confocal microscopes, fluorescence microscopes, zoom and stereo microscopes. Microscope slides and imaging reagents are available for visualizing samples, as well as various microscope stages and incubators for large or temperature-sensitive samples. Find the best light microscopes in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Cancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.ImagingImaging techniques are essential for obtaining visual representations of samples to understand structures, processes, and function in biological, chemical, and physical research. These tools range from traditional light microscopy to advanced imaging modalities like MRI and electron microscopy, providing researchers with valuable data for diagnostics, drug discovery, and material analysis. Explore imaging solutions in our peer-reviewed product directory to compare products, check reviews, and get pricing directly from manufacturers.Biomarker DiscoveryClinical biomarkers refer to substances related to known medical conditions that can be accurately measured <i>in vitro</i>. Biomarkers can be used to diagnose presence of a disease and indicate disease severity. The discovery of new biomarkers is incredibly valuable in the field of diagnostics.